VTRS Viatris Inc Total Asset Value of Company

VTRS (Viatris Corp) - company brandmark

Viatris Inc. (VTRS) is exposed to threats of disrupted logistics chains from Asia and patent law complexities stemming from global conflicts. Updated technical processes and the absence of plant downtime support business stability. This chart reflects the price trend of total assets, which stands at 36669.64, confirming the holding's resilience through global market reach with affordable drug analogues.

VTRS (Viatris Inc.) Company Total Assets history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Viatris Corp (VTRS)

- current quotes and average value forecast:
Market Chart viatris.com|VTRS - Price Target Chart
- market capitalization data:
Market Valuation Mylan|VTRS - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Viatris|VTRS - Book Capitalization|Market Capitalization to Book Value Ratio viatris.com|VTRS - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Viatris Inc.|VTRS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Mylan|VTRS - Company Aggregate Debts|Debts to Book Capitalization Mylan|VTRS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Viatris|Intermediate Coverage Ratio viatris.com
- net income and valuation multiples indicators:
VTRS - Company Net Income
Fundamental valuation:Viatris Inc.
Manufactured products of Viatris Inc.

For Viatris Inc. (VTRS), the total assets level demonstrates the scale of the resource base supporting global generic distribution despite logistical barriers. This indicator aggregates the value of all controlled resources, including equity and external liabilities. The value is calculated inversely via return on assets (ROA), reflecting the balance sheet's sensitivity to the cost of debt financing. This trend allows investors to assess the company's resilience to shifting economic cycles.

Key competitors

LLY - Company Total Asset Base|Aggregate Company Assets AbbVie|AstraZeneca Plc - Total Asset Value of Company|Company Total Assets NVS|MRK (MSD) - Aggregate Asset Value|Company Total Assets NVO (Novo Nordisk A/S)|Company Total Assets amgen.com AMGN|PFE - Aggregate Company Assets|Aggregate Asset Value SNY (Sanofi SA)|BMS (BMY) - Aggregate Company Assets|Cumulative Company Assets GlaxoSmithKline|TAK (Takeda Pharmaceutical) - Company Total Assets|Company Total Assets Teva Pharma|Cumulative Company Assets RDY (Dr. Reddy's)|ROIV (Roivant) - Aggregate Asset Value|Company Total Assets ZLAB (Zai Lab Ltd.)|Aggregate Asset Value BHC|COSM - Aggregate Company Assets